Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-2102 in healthy male subjects
NCT02397005Phase 1Unknown
- Sponsor
- Zai Lab
- Start
- Mar 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZL-2102 in chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Zai Lab. Primary endpoints: Safety as measured by Adverse Events at 21 days, Peak Plasma Concentration of ZL-2102 at 48 hours and 1 more. Status: unknown.
02
Drugs
ZL-2102
03
Conditions
chronic obstructive pulmonary disease (COPD)asthmaidiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02397005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397005.